Related Experiment Video
Updated: Dec 31, 2025
10:10
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
1.8K
Sustained Nitric Oxide-Providing Small Molecule and Precise Release Behavior Study for Glaucoma Treatment.
Hyejoong Jeong1, Sujin Park2, Kyungtae Park1
1Department of Chemical and Biomolecular Engineering , Yonsei University , Seoul 03722 , Republic of Korea.
Molecular Pharmaceutics
|January 9, 2020
Summary
A novel nitric oxide-releasing material (NOP) effectively lowers intraocular pressure (IOP) by relaxing the trabecular meshwork. This breakthrough offers a promising new avenue for glaucoma treatment without adverse side effects.
Area of Science:
- Ophthalmology
- Biomaterials Science
- Drug Delivery
Background:
- Glaucoma incidence is rising globally due to aging populations, causing irreversible vision loss.
- Lowering intraocular pressure (IOP) is the primary treatment for glaucoma.
- Nitric oxide (NO) shows potential for IOP reduction by relaxing the trabecular meshwork (TM), but effective, non-toxic levels are unclear.
Purpose of the Study:
- To develop and evaluate a novel long-term nitric oxide-releasing polydiazeniumdiolate (NOP) for glaucoma treatment.
- To investigate the NO release profile of NOP and its effect on IOP.
- To assess the safety and efficacy of NOP in relaxing the trabecular meshwork and lowering IOP.
Main Methods:
- Synthesis of a novel carbon-bound polydiazeniumdiolate (NOP) as a stable NO donor.
- Real-time monitoring of NO release from NOP and analysis of release profiles.
- In vivo evaluation of NOP's effect on TM relaxation and IOP in a glaucoma model.
Main Results:
- NOP demonstrated controlled, long-term nitric oxide release.
- The material effectively relaxed the trabecular meshwork in vitro.
- In vivo studies showed a potential IOP-lowering effect with NOP without observable side effects.
Conclusions:
- NOP is a promising novel material for glaucoma management through the conventional outflow pathway.
- Understanding NO release kinetics is crucial for developing safe and effective IOP-lowering therapies.
- This study provides valuable insights into NO-based glaucoma treatment strategies.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
905
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
905
01:28Nitric Oxide Signaling Pathway
6.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.0K
01:28Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
01:23Antihypertensive Drugs: Vasodilators
1.9K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
1.9K
01:25Glaucoma: Overview
1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
01:16Antianginal Drugs: Nitrates and β-Blockers
1.3K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.3K